DaVita (NYSE:DVA) Hits New 12-Month High – Here’s Why

Shares of DaVita Inc. (NYSE:DVA) hit a new 52-week high during trading on Monday . The company traded as high as $179.60 and last traded at $175.61, with a volume of 508351 shares traded. The stock had previously closed at $176.50.

Wall Street Analysts Forecast Growth

Separately, Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Stock Up 0.2 %

The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm has a market cap of $14.55 billion, a PE ratio of 19.14, a P/E/G ratio of 0.86 and a beta of 0.93. The business’s 50-day simple moving average is $160.10 and its 200 day simple moving average is $155.85.

Hedge Funds Weigh In On DaVita

Large investors have recently bought and sold shares of the business. Transcendent Capital Group LLC purchased a new position in shares of DaVita in the 3rd quarter valued at $25,000. Blue Trust Inc. boosted its position in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after purchasing an additional 119 shares in the last quarter. Quarry LP purchased a new position in DaVita in the third quarter valued at about $60,000. Venturi Wealth Management LLC raised its holdings in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Versant Capital Management Inc boosted its holdings in shares of DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.